Legal Guidance and Research / Experts / Anastasia Vernikou
Anastasia Vernikou#12086

Anastasia Vernikou

Hogan Lovells
Anastasia Vernikou advises life sciences companies on EU law and regulation governing medical devices, digital health solutions, biotechnology, and medicinal products. Anastasia is a member of the Global Regulatory Life Sciences team of Hogan Lovells and is qualified to practice law in Greece. 

Practice Area

Panel

  • Contributing Author

Qualified Year

  • 2021

Experience

  • World Health Organization (2021 - 2022)
  • Cooley LLP (2022 - 2023)
  • Hogan Lovells (2023 - Present)

Qualifications

  • Law Degree (“Ptychion”) (2018)
  • Admission to the Greek Bar (2021)
  • Admission to the Brussels Bar – E List (2022)
  • Bachelor of Laws (2018)
  • LL.M. in Global Health Law (2020)
  • LL.M. in IP and ICT Law (2022)

Education

  • National and Kapodistrian University of Athens (2018)
  • Georgetown University Law Center (2020)
  • Catholic University of Leuven (2022)

1 Contributions by Anastasia Vernikou

Falsified medicinal products: EU FMD and UK post‑Brexit regimes (including the Windsor Framework), active substance controls, supply chain obligations, online sales logo, safety features and UK‑only labelling
PRACTICE NOTES
Falsified medicinal products: EU FMD and UK post‑Brexit regimes (including the Windsor Framework), active substance controls, supply chain obligations, online sales logo, safety features and UK‑only labelling
Across both advanced and developing nations, the commerce in falsified medicinal products is a global problem. The labels ‘falsified medicines’ and ‘counterfeit medicines’ must not be conflated—falsified medicines are fake items crafted to imitate genuine treatments, while counterfeit medicines are those that breach trade marks or other intellectual property rights. This Practice Note reviews the regulatory changes introduced by Directive 2011/62/EU on preventing the entry of falsified medicinal products into the legitimate supply chain (the Falsified Medicines Directive, FMD), aimed at addressing the growing incidence of falsified medicines. It first explains the meaning of ‘falsified medicinal product’, then outlines the FMD’s measures, including: tighter oversight of active substances duties placed on participants within the supply chain safety features added to medicinal product packaging a common logo for websites that sell medicinal products This Practice Note also sets out an overview of the EU and UK frameworks on falsified medicines. EU regulatory framework—Falsified Medicines Directive The FMD recognises a troubling rise in medicinal products identified within the EU that are falsified and which reach patients through illegal routes and via the legal supply...
Life Sciences
Expert page AD
If you expected to see yourself on this page, click here.